Practical considerations in medical cannabis administration and dosing.

Citation data:

European journal of internal medicine, ISSN: 1879-0828, Vol: 49, Page: 12-19

Publication Year:
2018
Captures 73
Readers 73
Mentions 8
News Mentions 6
Blog Mentions 2
Social Media 201
Shares, Likes & Comments 126
Tweets 75
Citations 1
Citation Indexes 1
PMID:
29307505
DOI:
10.1016/j.ejim.2018.01.004
Author(s):
MacCallum, Caroline A; Russo, Ethan B
Publisher(s):
Elsevier BV
Tags:
Medicine
Most Recent Tweet View All Tweets
Most Recent Blog Mention
Most Recent News Mention
review description
Cannabis has been employed medicinally throughout history, but its recent legal prohibition, biochemical complexity and variability, quality control issues, previous dearth of appropriately powered randomised controlled trials, and lack of pertinent education have conspired to leave clinicians in the dark as to how to advise patients pursuing such treatment. With the advent of pharmaceutical cannabis-based medicines (Sativex/nabiximols and Epidiolex), and liberalisation of access in certain nations, this ignorance of cannabis pharmacology and therapeutics has become untenable. In this article, the authors endeavour to present concise data on cannabis pharmacology related to tetrahydrocannabinol (THC), cannabidiol (CBD) et al., methods of administration (smoking, vaporisation, oral), and dosing recommendations. Adverse events of cannabis medicine pertain primarily to THC, whose total daily dose-equivalent should generally be limited to 30mg/day or less, preferably in conjunction with CBD, to avoid psychoactive sequelae and development of tolerance. CBD, in contrast to THC, is less potent, and may require much higher doses for its adjunctive benefits on pain, inflammation, and attenuation of THC-associated anxiety and tachycardia. Dose initiation should commence at modest levels, and titration of any cannabis preparation should be undertaken slowly over a period of as much as two weeks. Suggestions are offered on cannabis-drug interactions, patient monitoring, and standards of care, while special cases for cannabis therapeutics are addressed: epilepsy, cancer palliation and primary treatment, chronic pain, use in the elderly, Parkinson disease, paediatrics, with concomitant opioids, and in relation to driving and hazardous activities.